Section Arrow
Quote
ATOS.NASDAQ
- Atossa Therapeutics Inc.
Quotes are at least 15-min delayed:2026/05/27 02:37 EDT
Regular Hours
Last
 4.95
-0.01 (-0.20%)
Day High 
5.055 
Prev. Close
4.96 
1-M High
6.18 
Volume 
30.31K 
Bid
4.85
Ask
5.1
Day Low
4.8631 
Open
4.95 
1-M Low
4.66 
Market Cap 
42.71M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 5.01 
20-SMA 5.28 
50-SMA 5.3 
52-W High 19.35 
52-W Low 3.76 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-4.37/-2.72
Enterprise Value
42.71M
Balance Sheet
Book Value Per Share
3.54
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
OTLKOutlook Therapeutics0.4002+0.0903+29.14%-- 
SNGXSoligenix Inc.0.513+0.1229+31.50%-- 
PHGEBiomX Inc.1.62+0.8035+98.41%-- 
RXRXRecursion Pharmaceuticals2.97-0.04-1.33%-- 
ARTLArtelo Biosciences Inc1.71+0.52+43.70%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.